ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Metformin

Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.

Drug pageMetformin: every studyMany companies study it; this page follows only the 215 they lead. All 1,290 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 9, 2005215 company-led studies, 7 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca290 open or runningphase 3since Nov 9, 2005Nov 9, 2005none ahead
Merckits history only190 open or runningphase 4since Oct 9, 2009Feb 15, 2005none ahead
Sanofiits history only160 open or runningphase 4since Jul 28, 2006Sep 30, 2002none ahead
GlaxoSmithKlineits history only140 open or runningphase 4since Oct 17, 2005Sep 3, 2003none ahead
Takedaits history only120 open or runningphase 4since Sep 17, 2008Jul 30, 2008none ahead
Merck KGaA, Darmstadt, Germanyits history only90 open or runningphase 4since Dec 30, 2011Dec 30, 2011none ahead
Teva Pharmaceutical Industriesits history only90 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatrisits history only80 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
ADIUMits history only70 open or runningno phasesince Jun 3, 2026Jun 3, 2026none ahead
LG Chemits history only70 open or runningphase 3since Feb 6, 2013Aug 22, 2011none ahead

Also a collaborator on its studies: Parexel, PT Pharma Metric Labs, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly and Merck, S.L., Spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Nov 9, 2005.

  1. Feb 25, 2011Phase 1 study in Diabetes Mellitus, Type 2NCT01305551 · Brazil
  2. May 16, 2011Phase 1 study in Diabetes Mellitus, Type 2NCT01365091 · 112 enrolled · Brazil
  3. Sep 26, 2011Phase 1 study in Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and MetforminNCT01441869 · 28 enrolled · United States
  4. Jan 31, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01525225 · 4 enrolled · United States
  5. Dec 12, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01755494 · 64 enrolled · China
  6. Jun 6, 2013Phase 1 study in Diabetes MellitusNCT01874080 · 56 enrolled · United States
  7. Oct 22, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02273050 · 1,136 enrolled · China
  8. Sep 15, 2015Phase 3 study in Diabetes Mellitus, Type 2NCT02551874 · 650 enrolled · United States, Czechia, Denmark and more
  9. Dec 15, 2015Phase 1 study in Diabetes Mellitus, Type 2NCT02637037 · 80 enrolled · United States
  10. Mar 15, 2016Phase 1 study in Diabetes Mellitus, Type 2NCT02722239 · 40 enrolled · Russian Federation
  11. Apr 7, 20172 phase 1 studiesNCT03216278, NCT03138356
  12. May 23, 2017Phase 1 study in Diabetes Mellitus, Type 2NCT03169959 · 85 enrolled · United States
  13. Mar 3, 2023Phase 1 study in Healthy Male SubjectsNCT05768360 · 6 enrolled · Germany
  14. Nov 29, 2023Phase 1 study in HealthyNCT06160414 · 20 enrolled · United Kingdom

TargetBeta

“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

All 29 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06160414Healthy · United Kingdom1CompletedFeb 5, 202420
NCT05768360Healthy Male Subjects · Germany1CompletedJun 24, 20236
NCT03169959Diabetes Mellitus, Type 2 · United States1CompletedAug 3, 201785
NCT03138356Diabetes Mellitus, Type 2 · United Kingdom1CompletedNov 28, 2017126
NCT03216278Lecithin Cholesterol Acyltransferase Deficiency · Brazil1CompletedMay 22, 2018284
NCT02722239Diabetes Mellitus, Type 2 · Russian Federation1CompletedMay 5, 201640
NCT02637037Diabetes Mellitus, Type 2 · United States1CompletedApr 7, 201680
NCT02551874Diabetes Mellitus, Type 2 · United States, Czechia, Denmark and more3CompletedMay 8, 2017650
NCT02273050Diabetes Mellitus, Type 2 · China3CompletedAug 20161,136
NCT01874080Diabetes Mellitus · United States1CompletedJul 201356
NCT01755494Diabetes Mellitus, Type 2 · China1CompletedApr 201364
NCT01525225Diabetes Mellitus, Type 2 · United States1TerminatedJun 20134
NCT01441869Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin · United States1CompletedDec 201128
NCT01365091Diabetes Mellitus, Type 2 · Brazil1CompletedNov 2011112
NCT01305551Diabetes Mellitus, Type 2 · Brazil1WithdrawnMar 20110
NCT01192152Diabetes Mellitus · United States1CompletedDec 200930
NCT01192139Diabetes Mellitus · United States1CompletedDec 200930
NCT01095666Diabetes Mellitus, Type 2 · China, India, Korea, Republic of3CompletedMar 20131,484
NCT01068743Diabetes Mellitus, Type 2 · United States1CompletedMar 201024
NCT01068730Diabetes Mellitus, Type 2 · United States1CompletedApr 201028
NCT01055691Healthy Volunteers · Germany1CompletedApr 2010120
NCT01002807Diabetes Mellitus, Type 2 · United States1CompletedDec 200915
NCT00897390Diabetes Mellitus, Type 2 · United States1CompletedJul 200924
NCT00859898Diabetes Mellitus, Type 2 · United States, India, Korea, Republic of and more3CompletedMay 20101,093
NCT00643851Diabetes Mellitus, Type 2 · United States, Korea, Republic of, Mexico and more3CompletedAug 2009994
NCT00327015Diabetes Mellitus · United States, Argentina, Brazil and more3CompletedNov 20071,306
NCT00263965Diabetes Mellitus, Type 2 · Finland, Italy, United Kingdom2Terminated105
NCT00261352Diabetes Mellitus, Type 2 · Brazil, Canada, Finland and more3Terminated1,000
NCT00251953Diabetes Mellitus, Type 2 · Australia, Canada, Finland and more3Terminated555

How it is read

Names in the registry

  • “Metformin”, 95 entries
  • “metformin”, 33 entries
  • “Metformin XR”, 11 entries
  • “Fenofibrate /Metformin”, 6 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: EFB0027.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.